niftify.in

Business Standard

Orchid AMS eyes Rs 300 cr turnover in 3 years for antimicrobial resistance

Orchid Pharma's newly-formed antimicrobial solutions division is targeting a turnover of up to Rs 300 crore in the next three years with about 250 strong salespeople onboard while combating the challenge of antimicrobial resistance in India, according to a top company official. Orchid AMS (Antimicrobial Solutions) is targeting to partner with around 2,500-3,000 hospitals and healthcare institutions in the next two to three years to implement effective antimicrobial stewardship programmes (AMSPs). Antimicrobial resistance is one of the biggest healthcare challenges beyond the hospitals as medications are available easily without prescriptions and antibiotics are also coming in through poultry, fish and through crops, Rajnish Rohatgi, CEO, Orchid AMS, a division of Orchid Pharma, told PTI. "This is a humongous issue. We felt that not only from a business aspect of creating a difference but it provides us a motivating purpose beyond business and to give back to society in our own way,

CNBC TV18

A greed and no fear report from India’s manic IPO market

The recent rally has led people to believe that the stock market is Phir Hera Pheri's Laxmi Chit Fund that would double their money in 21 days, give them the capital for a poultry farm, which would make them ‘Bread ka Badshah’ and ‘Omelette ka Raja’ as Andaz Apna Apna's Teja aspired to be.

The Economic Times

Government considers ban on two antibiotics

The government is considering banning the production, import, and distribution of chloramphenicol and nitrofurans antibiotics used in food-producing animal rearing systems, due to misuse in poultry and animal feed supplements.